Income Statement Oxford Nanopore Technologies plc
Equities
ONT
GB00BP6S8Z30
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123.60 GBX | +2.57% |
|
+7.11% | -3.74% |
| 04-20 | Roadside Real Estate CEO buys after Hoch purchase | AN |
| 04-15 | Cepheid and Oxford Nanopore Technologies Expand Partnership for Infectious Disease Research Collaboration | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 134M | 199M | 170M | 183M | 224M | |||||
Total Revenues | 134M | 199M | 170M | 183M | 224M | |||||
Cost of Goods Sold, Total | 60.47M | 74.79M | 79.19M | 77.8M | 87.5M | |||||
Gross Profit | 73.2M | 124M | 90.48M | 105M | 136M | |||||
Selling General & Admin Expenses, Total | 162M | 157M | 155M | 157M | 180M | |||||
R&D Expenses | 75.98M | 64.84M | 103M | 98.47M | 89.4M | |||||
Depreciation & Amortization - (IS) | - | - | - | - | - | |||||
Other Operating Expenses | - | - | 889K | 2.73M | -1.8M | |||||
Other Operating Expenses, Total | 238M | 222M | 259M | 258M | 268M | |||||
Operating Income | -165M | -98.48M | -169M | -152M | -131M | |||||
Interest Expense, Total | -908K | -1.63M | -2.21M | -3.56M | -2.8M | |||||
Interest And Investment Income | 224K | 5.94M | 18.85M | 14.84M | 11.8M | |||||
Net Interest Expenses | -684K | 4.31M | 16.65M | 11.28M | 9M | |||||
Income (Loss) On Equity Invest. | -64K | -238K | -228K | -18K | - | |||||
Currency Exchange Gains (Loss) | 504K | -5.43M | 2.12M | -151K | - | |||||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||||
EBT, Excl. Unusual Items | -165M | -99.84M | -150M | -141M | -122M | |||||
Restructuring Charges | - | - | - | - | -20.8M | |||||
Gain (Loss) On Sale Of Investments | -1.23M | -2.19M | 297K | 1.26M | 8.2M | |||||
Gain (Loss) On Sale Of Assets | - | 18.62M | - | - | - | |||||
Asset Writedown | - | - | - | - | -5.1M | |||||
EBT, Incl. Unusual Items | -166M | -83.41M | -150M | -140M | -140M | |||||
Income Tax Expense | 1.61M | 7.61M | 4.74M | 6.23M | 5.3M | |||||
Earnings From Continuing Operations | -168M | -91.02M | -155M | -146M | -145M | |||||
Net Income to Company | -168M | -91.02M | -155M | -146M | -145M | |||||
Net Income - (IS) | -168M | -91.02M | -155M | -146M | -145M | |||||
Net Income to Common Incl Extra Items | -168M | -91.02M | -155M | -146M | -145M | |||||
Net Income to Common Excl. Extra Items | -168M | -91.02M | -155M | -146M | -145M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.23 | -0.11 | -0.19 | -0.16 | -0.15 | |||||
Basic EPS - Continuing Operations | -0.23 | -0.11 | -0.19 | -0.16 | -0.15 | |||||
Basic Weighted Average Shares Outstanding | 732M | 824M | 834M | 898M | 961M | |||||
Net EPS - Diluted | -0.23 | -0.11 | -0.19 | -0.16 | -0.15 | |||||
Diluted EPS - Continuing Operations | -0.23 | -0.11 | -0.19 | -0.16 | -0.15 | |||||
Diluted Weighted Average Shares Outstanding | 732M | 824M | 834M | 898M | 961M | |||||
Normalized Basic EPS | -0.14 | -0.08 | -0.11 | -0.1 | -0.08 | |||||
Normalized Diluted EPS | -0.14 | -0.08 | -0.11 | -0.1 | -0.08 | |||||
American Depositary Receipts Ratio (ADR) | 4 | 4 | 4 | 4 | 4 | |||||
Supplemental Items | ||||||||||
EBITDA | -152M | -82.46M | -150M | -139M | -116M | |||||
EBITA | -164M | -98.43M | -169M | -152M | -131M | |||||
EBIT | -165M | -98.48M | -169M | -152M | -131M | |||||
EBITDAR | - | - | -150M | -138M | -114M | |||||
Effective Tax Rate - (Ratio) | -0.97 | -9.13 | -3.16 | -4.45 | -3.79 | |||||
Total Current Taxes | 6.16M | 7.92M | 4.52M | 3.99M | 4.1M | |||||
Total Deferred Taxes | -4.56M | -310K | 214K | 2.24M | 1.2M | |||||
Normalized Net Income | -103M | -62.4M | -93.79M | -88.27M | -76.38M | |||||
Interest on Long-Term Debt | 908K | 1.63M | 2.2M | 3.56M | 2.8M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | - | - | - | - | - | |||||
Research And Development Expense From Footnotes | 75.98M | 64.84M | 104M | 98.92M | 97.7M | |||||
Net Rental Expense, Total | - | - | 928K | 971K | 1.2M | |||||
Imputed Operating Lease Interest Expense | - | - | 432K | 632K | 614K | |||||
Imputed Operating Lease Depreciation | - | - | 496K | 339K | 586K | |||||
Stock-Based Comp., SG&A Exp. (Total) | - | - | 20.89M | -6.15M | 200K | |||||
Stock-Based Comp., Other (Total) | 62.45M | 70.01M | 14.02M | 10.07M | 20M | |||||
Total Stock-Based Compensation | 62.45M | 70.01M | 34.91M | 3.92M | 20.2M |
- Stock Market
- Equities
- ONT Stock
- Financials Oxford Nanopore Technologies plc
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















